fda bpc-157 warning letter letters target marketers of unapproved weight loss drugs FDA panel narrowly backs unapproved

148 ShiY.ZhangW.YangY.MurzinA.FalconB.KotechaA.et al (2021)

For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatru/Cagrilintide is a dual-compound research peptide combining Retatru, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways, and Cagrilintide, an amylin analog

Clinical trial data published in recent years has placed retatrutide among the more closely watched compounds in obesity and metabolic dysfunction research

This regulatory environment creates uncertainty

Cagrilintide is not yet approved by regulators, no dosing recommendations for human use exist